Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03723434 (ClinicalTrials.gov)	May 31, 2017	22/10/2018	Physiology of Interregional Connectivity in the Human Brain	Physiology of Interregional Connectivity in the Human Brain	Healthy;Stroke;Traumatic Brain Injury;Multiple Sclerosis	Device: Single-pulse transcranial magnetic stimulation (spTMS);Device: Paired associative stimulation (PAS);Device: Repetitive transcranial magnetic stimulation (rTMS)	Shirley Ryan AbilityLab	Northwestern University	Unknown status	18 Years	85 Years	All	76	N/A	United States
2	NCT01453868 (ClinicalTrials.gov)	October 2011	13/10/2011	The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis	The Effects of Neuromuscular Training on Balance in Patients With Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Other: Non Impact Aerobics;Other: Passive : lecture series	Nelson Mandela Metropolitan University	NULL	Recruiting	20 Years	60 Years	Both	60	Phase 0	United States
3	NCT00461396 (ClinicalTrials.gov)	May 2007	17/4/2007	Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron	Open-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment With 250mcg (8MIU) IFNB-1b (Betaseron®) Given Subcutaneous Every Other Day Over a Period of up to 12 Months in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis and Patients With Onset of Relapsing-Remitting Multiple Sclerosis (RRMS) Within the Past 12 Months	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon-1beta (Betaseron, BAY86-5046)	Bayer	NULL	Completed	18 Years	50 Years	Both	104	Phase 4	United States
4	EUCTR2006-000606-23-ES (EUCTR)	23/11/2006	15/03/2012	?Post-authorization safety study to check the potential association between the safetyprofile of beta interferon 1a and the body mass index or pharmacodynamics during thetitration phase	Post-authorization safety study to check the potential association between the safetyprofile of beta interferon 1a and the body mass index or pharmacodynamics during thetitration phase - PASS-PD del escalado de dosis de Rebif	Not applicalbe MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rebif 22 y 44 mcg Product Name: Interferon-beta -1a Other descriptive name: INTERFERON BETA -1A	Merck, S.L.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Spain